A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 26, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

May 1, 2025

Conditions

Chronic Hepatitis B

Interventions

DRUG

GST-HG131

GST-HG131 will be administered.

DRUG

Placebo to match GST-HG131

Placebo to match GST-HG131 will be administered.

Trial Locations (1)

RECRUITING

The Fifth Medical Center of Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Fujian Akeylink Biotechnology Co., Ltd.

INDUSTRY